Wechselwirkungen · Repaglinide Teva
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210744 · Präparat HOS-154579
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0–∞) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0–∞) 3.9-fold. A small, significant decrease in blood glucose values was observed. Since the safety profile of the co-treatment has not been established in these patients, the concomitant use of clopidogrel and repaglinide should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-11T17:40:00Z · SHA-256 7ea88aaeb62655814b4cbb82e87f581c1d76d8e897c814045f52ed8ce0706612 · Passage 56d4dedf2afd90d365a5bce8e2c7892aaff5e60aebc849784f195feb2c6031de · Zeichen 6173–6809 im Abschnitt